The inaugural MQPH 2018 Conference will take place at Keble College, Oxford from 23 – 28 September 2018, and will bring together people from a diversity of sectors. There has never been an opportunity for the diverse stakeholders involved in medicine quality and drug regulation to come together before – within the framework of a specific academic conference – to share ideas and expertise, and to outline the coordinated steps that need to be taken to tackle the problem on an international scale. Registration for this Conference is now open
Deepen your understanding of the health challenges in resource limited contexts and learn about exciting developments in research to inform viable and sustainable solutions. Experience teaching from world-renowned academics on the cutting edge of health research in resource limited contexts while interacting with fellow leaders and decision makers from government ministries, multilateral and bilateral organisations. The course will take place at Exeter College, University of Oxford, 3rd to 7th September 2018
Dr Nicola Burgess-Brown heads the Biotechnology Group at the SGC, which generates proteins suitable for structural and functional studies. She explains how recombinant protein expression in host cells such as bacterial or insect cells facilitates the production of large amounts of proteins, which can be used for crystallisation to obtain the protein structure, or in cellular assays to look at their function. Collaborations with partners such as academics, industry and patient groups aim to find compounds that can be developed into potential drugs.
Researchers recently used DNA from the 10,000-year-old “Cheddar Man”, one of Britain’s oldest skeletons, to unveil what the first inhabitants of what now is Britain actually looked like. A recent article in The Conversation with Oxford Big Data Institute's George Busby explains how DNA from old skeletons has provided intriguing findings about our ancestors and how rapid advances in genetic sequencing over the past few decades have opened up a whole new window into the past.
Health Data Research UK is awarding £30 million funding to six sites across the UK, including the University of Oxford, to address challenging healthcare issues through use of data science. Professor Martin Landray, Director of the Health Data Research UK Oxford site said: 'We are delighted that the Big Data Institute at University of Oxford will play a major part in Health Data Research UK. This exciting endeavour brings new opportunities to understand the causes of disease and to develop new treatments with substantial benefits for patients and public health.'
A recent study published by Prof Najib Rahman, Clinical Director, Oxford Respiratory Trials Unit explains how 15% of people with malignant effusion develop septations (pockets) within the fluid, which are difficult to treat. TIME3 was a randomised trial assessing the use of intrapleural fibrinolytic, showing no improvement in breathlessness but improved x-ray appearance and possible mortality benefit. This study provides high quality evidence for the rational use of this medication for patients.
Thu 15 Feb 2018 1-2pm
Lecture Theatre 1
ICU: Dr Claire Colebourn and Dr Jodie Smythe "The hungry heart: echocardiographic changes in anorexia nervosa"
Renal: Dr Paul Harden and Dr Matthew Brook
"Not just a flash in the PAN - Diagnosis and longer term outcomes in polyarteritis nodosa"
Chair: Prof Hugh Watkins